<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 19:03:10 -0700</creation_date>
  <update_date>2013-05-27 11:35:01 -0600</update_date>
  <accession>HMDBP02165</accession>
  <secondary_accessions>
    <accession>7649</accession>
    <accession>HMDBP03539</accession>
  </secondary_accessions>
  <protein_type>Transporter</protein_type>
  <synonyms>
    <synonym>5HT transporter</synonym>
    <synonym>5HTT</synonym>
    <synonym>Solute carrier family 6 member 4</synonym>
  </synonyms>
  <gene_name>SLC6A4</gene_name>
  <general_function>Involved in neurotransmitter:sodium symporter activity</general_function>
  <specific_function>Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin and recycles it in a sodium-dependent manner.
</specific_function>
  <pathways>
    <pathway>
      <name>Serotonergic synapse</name>
      <smpdb_id/>
      <kegg_map_id>map04726</kegg_map_id>
    </pathway>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00588</accession>
      <name>Sodium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01848</accession>
      <name>Imipramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05016</accession>
      <name>Venlafaxine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05038</accession>
      <name>Citalopram</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01920</accession>
      <name>Dextromethorphan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00259</accession>
      <name>Serotonin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05028</accession>
      <name>Escitalopram</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05010</accession>
      <name>Sertraline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14322</accession>
      <name>Fluvoxamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14337</accession>
      <name>Phentermine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14339</accession>
      <name>Tramadol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14021</accession>
      <name>N-Desmethylcitalopram</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14434</accession>
      <name>Atomoxetine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14488</accession>
      <name>Protriptyline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14566</accession>
      <name>Methylphenidate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14619</accession>
      <name>Duloxetine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14680</accession>
      <name>Nortriptyline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14683</accession>
      <name>Amoxapine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14718</accession>
      <name>Mazindol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14794</accession>
      <name>Trazodone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13961</accession>
      <name>O-Desmethylverapamil (D-702)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14853</accession>
      <name>Paroxetine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14864</accession>
      <name>Trimipramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14943</accession>
      <name>Minaprine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15043</accession>
      <name>Cocaine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15237</accession>
      <name>Sibutramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15273</accession>
      <name>Doxepin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15280</accession>
      <name>Nefazodone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15282</accession>
      <name>Desipramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15322</accession>
      <name>Dexfenfluramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15372</accession>
      <name>Clomipramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15517</accession>
      <name>Methamphetamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15602</accession>
      <name>Milnacipran</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15620</accession>
      <name>Mianserin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15637</accession>
      <name>Vilazodone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15646</accession>
      <name>Desvenlafaxine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15647</accession>
      <name>Dexmethylphenidate</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>serotonin:sodium symporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>neurotransmitter transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>neurotransmitter:sodium symporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>establishment of localization</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>neurotransmitter transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intrinsic to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>integral to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>integral to plasma membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>cytosol</description>
      <go_id>GO:0005829</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>endomembrane system</description>
      <go_id>GO:0012505</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>endosome membrane</description>
      <go_id>GO:0010008</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>integral to plasma membrane</description>
      <go_id>GO:0005887</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>membrane raft</description>
      <go_id>GO:0045121</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>actin filament binding</description>
      <go_id>GO:0051015</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>cocaine binding</description>
      <go_id>GO:0019811</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>serotonin transmembrane transporter activity</description>
      <go_id>GO:0015222</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>serotonin:sodium symporter activity</description>
      <go_id>GO:0005335</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>brain morphogenesis</description>
      <go_id>GO:0048854</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>cellular response to cGMP</description>
      <go_id>GO:0071321</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>cellular response to retinoic acid</description>
      <go_id>GO:0071300</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>circadian rhythm</description>
      <go_id>GO:0007623</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>memory</description>
      <go_id>GO:0007613</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>negative regulation of cerebellar granule cell precursor proliferation</description>
      <go_id>GO:0021941</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>negative regulation of neuron differentiation</description>
      <go_id>GO:0045665</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>negative regulation of organ growth</description>
      <go_id>GO:0046621</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>negative regulation of synaptic transmission, dopaminergic</description>
      <go_id>GO:0032227</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of cell cycle</description>
      <go_id>GO:0045787</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of gene expression</description>
      <go_id>GO:0010628</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>protein homooligomerization</description>
      <go_id>GO:0051260</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>protein oligomerization</description>
      <go_id>GO:0051259</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to drug</description>
      <go_id>GO:0042493</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to estradiol stimulus</description>
      <go_id>GO:0032355</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to hypoxia</description>
      <go_id>GO:0001666</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to nutrient</description>
      <go_id>GO:0007584</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to toxin</description>
      <go_id>GO:0009636</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>serotonin uptake</description>
      <go_id>GO:0051610</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>social behavior</description>
      <go_id>GO:0035176</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>sperm ejaculation</description>
      <go_id>GO:0042713</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>thalamus development</description>
      <go_id>GO:0021794</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>vasoconstriction</description>
      <go_id>GO:0042310</go_id>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Cell membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
    <subcellular_location>Endomembrane system</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
    <subcellular_location>Endosome membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>17</chromosome_location>
    <locus>17q11.2</locus>
    <gene_sequence>&gt;1893 bp
ATGGAGACGACGCCCTTGAATTCTCAGAAGCAGCTATCAGCGTGTGAAGATGGAGAAGAT
TGTCAGGAAAACGGAGTTCTACAGAAGGTTGTTCCCACCCCAGGGGACAAAGTGGAGTCC
GGGCAAATATCCAATGGGTACTCAGCAGTTCCAAGTCCTGGTGCGGGAGATGACACACGG
CACTCTATCCCAGCGACCACCACCACCCTAGTGGCTGAGCTTCATCAAGGGGAACGGGAG
ACCTGGGGCAAGAAGGTGGATTTCCTTCTCTCAGTGATTGGCTATGCTGTGGACCTGGGC
AATGTCTGGCGCTTCCCCTACATATGTTACCAGAATGGAGGGGGGGCATTCCTCCTCCCC
TACACCATCATGGCCATTTTTGGGGGAATCCCGCTCTTTTACATGGAGCTCGCACTGGGA
CAGTACCACCGAAATGGATGCATTTCAATATGGAGGAAAATCTGCCCGATTTTCAAAGGG
ATTGGTTATGCCATCTGCATCATTGCCTTTTACATTGCTTCCTACTACAACACCATCATG
GCCTGGGCGCTATACTACCTCATCTCCTCCTTCACGGACCAGCTGCCCTGGACCAGCTGC
AAGAACTCCTGGAACACTGGCAACTGCACCAATTACTTCTCCGAGGACAACATCACCTGG
ACCCTCCATTCCACGTCCCCTGCTGAAGAATTTTACACGCGCCACGTCCTGCAGATCCAC
CGGTCTAAGGGGCTCCAGGACCTGGGGGGCATCAGCTGGCAGCTGGCCCTCTGCATCATG
CTGATCTTCACTGTTATCTACTTCAGCATCTGGAAAGGCGTCAAGACCTCTGGCAAGGTG
GTGTGGGTGACAGCCACCTTCCCTTATATCATCCTTTCTGTCCTGCTGGTGAGGGGTGCC
ACCCTCCCTGGAGCCTGGAGGGGTGTTCTCTTCTACTTGAAACCCAATTGGCAGAAACTC
CTGGAGACAGGGGTGTGGATAGATGCAGCCGCTCAGATCTTCTTCTCTCTTGGTCCGGGC
TTTGGGGTCCTGCTGGCTTTTGCTAGCTACAACAAGTTCAACAACAACTGCTACCAAGAT
GCCCTGGTGACCAGCGTGGTGAACTGCATGACGAGCTTCGTTTCGGGATTTGTCATCTTC
ACAGTGCTCGGTTACATGGCTGAGATGAGGAATGAAGATGTGTCTGAGGTGGCCAAAGAC
GCAGGTCCCAGCCTCCTCTTCATCACGTATGCAGAAGCGATAGCCAACATGCCAGCGTCC
ACTTTCTTTGCCATCATCTTCTTTCTGATGTTAATCACGCTGGGCTTGGACAGCACGTTT
GCAGGCTTGGAGGGGGTGATCACGGCTGTGCTGGATGAGTTCCCACACGTCTGGGCCAAG
CGCCGGGAGCGGTTCGTGCTCGCCGTGGTCATCACCTGCTTCTTTGGATCCCTGGTCACC
CTGACTTTTGGAGGGGCCTACGTGGTGAAGCTGCTGGAGGAGTATGCCACGGGGCCCGCA
GTGCTCACTGTCGCGCTGATCGAAGCAGTCGCTGTGTCTTGGTTCTATGGCATCACTCAG
TTCTGCAGGGACGTGAAGGAAATGCTCGGCTTCAGCCCGGGGTGGTTCTGGAGGATCTGC
TGGGTGGCCATCAGCCCTCTGTTTCTCCTGTTCATCATTTGCAGTTTTCTGATGAGCCCG
CCACAACTACGACTTTTCCAATATAATTATCCTTACTGGAGTATCATCTTGGGTTACTGC
ATAGGAACCTCATCTTTCATTTGCATCCCCACATATATAGCTTATCGGTTGATCATCACT
CCAGGGACATTTAAAGAGCGTATTATTAAAAGTATTACCCCGGAGACACCAACAGAAATT
CCTTGTGGGGACATCCGCTTGAATGCTGTGTAA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>630</residue_number>
    <molecular_weight>70324.165</molecular_weight>
    <theoretical_pi>6.246</theoretical_pi>
    <pfams>
      <pfam>
        <name>5HT_transporter</name>
        <pfam_id>PF03491</pfam_id>
      </pfam>
      <pfam>
        <name>SNF</name>
        <pfam_id>PF00209</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
    </transmembrane_regions>
    <signal_regions>
    </signal_regions>
    <protein_sequence>&gt;Sodium-dependent serotonin transporter
METTPLNSQKQLSACEDGEDCQENGVLQKVVPTPGDKVESGQISNGYSAVPSPGAGDDTR
HSIPATTTTLVAELHQGERETWGKKVDFLLSVIGYAVDLGNVWRFPYICYQNGGGAFLLP
YTIMAIFGGIPLFYMELALGQYHRNGCISIWRKICPIFKGIGYAICIIAFYIASYYNTIM
AWALYYLISSFTDQLPWTSCKNSWNTGNCTNYFSEDNITWTLHSTSPAEEFYTRHVLQIH
RSKGLQDLGGISWQLALCIMLIFTVIYFSIWKGVKTSGKVVWVTATFPYIILSVLLVRGA
TLPGAWRGVLFYLKPNWQKLLETGVWIDAAAQIFFSLGPGFGVLLAFASYNKFNNNCYQD
ALVTSVVNCMTSFVSGFVIFTVLGYMAEMRNEDVSEVAKDAGPSLLFITYAEAIANMPAS
TFFAIIFFLMLITLGLDSTFAGLEGVITAVLDEFPHVWAKRRERFVLAVVITCFFGSLVT
LTFGGAYVVKLLEEYATGPAVLTVALIEAVAVSWFYGITQFCRDVKEMLGFSPGWFWRIC
WVAISPLFLLFIICSFLMSPPQLRLFQYNYPYWSIILGYCIGTSSFICIPTYIAYRLIIT
PGTFKERIIKSITPETPTEIPCGDIRLNAV</protein_sequence>
  </protein_properties>
  <genbank_protein_id>36433</genbank_protein_id>
  <uniprot_id>P31645</uniprot_id>
  <uniprot_name>SC6A4_HUMAN</uniprot_name>
  <pdb_ids>
  </pdb_ids>
  <genbank_gene_id>X70697</genbank_gene_id>
  <genecard_id>SLC6A4</genecard_id>
  <geneatlas_id>SLC6A4</geneatlas_id>
  <hgnc_id>HGNC:11050</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Lesch KP, Wolozin BL, Estler HC, Murphy DL, Riederer P: Isolation of a cDNA encoding the human brain serotonin transporter.  J Neural Transm Gen Sect. 1993;91(1):67-72.</reference_text>
      <pubmed_id>8452685</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ramamoorthy S, Bauman AL, Moore KR, Han H, Yang-Feng T, Chang AS, Ganapathy V, Blakely RD: Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2542-6.</reference_text>
      <pubmed_id>7681602</pubmed_id>
    </reference>
    <reference>
      <reference_text>Lesch KP, Wolozin BL, Murphy DL, Reiderer P: Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. J Neurochem. 1993 Jun;60(6):2319-22.</reference_text>
      <pubmed_id>7684072</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Carneiro AM, Blakely RD: Serotonin-, protein kinase C-, and Hic-5-associated redistribution of the platelet serotonin transporter. J Biol Chem. 2006 Aug 25;281(34):24769-80. Epub 2006 Jun 27.</reference_text>
      <pubmed_id>16803896</pubmed_id>
    </reference>
    <reference>
      <reference_text>Muller HK, Wiborg O, Haase J: Subcellular redistribution of the serotonin transporter by secretory carrier membrane protein 2. J Biol Chem. 2006 Sep 29;281(39):28901-9. Epub 2006 Jul 26.</reference_text>
      <pubmed_id>16870614</pubmed_id>
    </reference>
    <reference>
      <reference_text>Brenner B, Harney JT, Ahmed BA, Jeffus BC, Unal R, Mehta JL, Kilic F: Plasma serotonin levels and the platelet serotonin transporter.  J Neurochem. 2007 Jul;102(1):206-15. Epub 2007 May 15.</reference_text>
      <pubmed_id>17506858</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ahmed BA, Jeffus BC, Bukhari SI, Harney JT, Unal R, Lupashin VV, van der Sluijs P, Kilic F: Serotonin transamidates Rab4 and facilitates its binding to the C terminus of serotonin transporter. J Biol Chem. 2008 Apr 4;283(14):9388-98. Epub 2008 Jan 28.</reference_text>
      <pubmed_id>18227069</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ahmed BA, Bukhari IA, Jeffus BC, Harney JT, Thyparambil S, Ziu E, Fraer M, Rusch NJ, Zimniak P, Lupashin V, Tang D, Kilic F: The cellular distribution of serotonin transporter is impeded on serotonin-altered vimentin network. PLoS One. 2009;4(3):e4730. Epub 2009 Mar 9.</reference_text>
      <pubmed_id>19270731</pubmed_id>
    </reference>
    <reference>
      <reference_text>Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Shaw N, Lane CR, Lim EP, Kalyanaraman N, Nemesh J, Ziaugra L, Friedland L, Rolfe A, Warrington J, Lipshutz R, Daley GQ, Lander ES: Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet. 1999 Jul;22(3):231-8.</reference_text>
      <pubmed_id>10391209</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ozaki N, Goldman D, Kaye WH, Plotnicov K, Greenberg BD, Lappalainen J, Rudnick G, Murphy DL: Serotonin transporter missense mutation associated with a complex neuropsychiatric phenotype. Mol Psychiatry. 2003 Nov;8(11):933-6.</reference_text>
      <pubmed_id>14593431</pubmed_id>
    </reference>
    <reference>
      <reference_text>Kilic F, Murphy DL, Rudnick G: A human serotonin transporter mutation causes constitutive activation of transport activity. Mol Pharmacol. 2003 Aug;64(2):440-6.</reference_text>
      <pubmed_id>12869649</pubmed_id>
    </reference>
    <reference>
      <reference_text>Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R: Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003 Jul 18;301(5631):386-9.</reference_text>
      <pubmed_id>12869766</pubmed_id>
    </reference>
    <reference>
      <reference_text>Feinn R, Nellissery M, Kranzler HR: Meta-analysis of the association of a functional serotonin transporter promoter polymorphism with alcohol dependence. Am J Med Genet B Neuropsychiatr Genet. 2005 Feb 5;133B(1):79-84.</reference_text>
      <pubmed_id>15635638</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Fluvoxamine</name>
        <accession>HMDB14322</accession>
      </metabolite>
      <reference>
        <reference_text>Kakiuchi T, Tsukada H, Fukumoto D, Nishiyama S: Effects of aging on serotonin transporter availability and its response to fluvoxamine in the living brain: PET study with [(11)C](+)McN5652 and [(11)C](-)McN5652 in conscious monkeys. Synapse. 2001 Jun 1;40(3):170-9.</reference_text>
        <pubmed_id>11304754</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluvoxamine</name>
        <accession>HMDB14322</accession>
      </metabolite>
      <reference>
        <reference_text>Yoshida K, Ito K, Sato K, Takahashi H, Kamata M, Higuchi H, Shimizu T, Itoh K, Inoue K, Tezuka T, Suzuki T, Ohkubo T, Sugawara K, Otani K: Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Feb;26(2):383-6.</reference_text>
        <pubmed_id>11817517</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluvoxamine</name>
        <accession>HMDB14322</accession>
      </metabolite>
      <reference>
        <reference_text>Miolo G, Caffieri S, Levorato L, Imbesi M, Giusti P, Uz T, Manev R, Manev H: Photoisomerization of fluvoxamine generates an isomer that has reduced activity on the 5-hydroxytryptamine transporter and does not affect cell proliferation. Eur J Pharmacol. 2002 Aug 30;450(3):223-9.</reference_text>
        <pubmed_id>12208313</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluvoxamine</name>
        <accession>HMDB14322</accession>
      </metabolite>
      <reference>
        <reference_text>Suhara T, Takano A, Sudo Y, Ichimiya T, Inoue M, Yasuno F, Ikoma Y, Okubo Y: High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch Gen Psychiatry. 2003 Apr;60(4):386-91.</reference_text>
        <pubmed_id>12695316</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluvoxamine</name>
        <accession>HMDB14322</accession>
      </metabolite>
      <reference>
        <reference_text>Inoue K: [Analysis and its application for prevention of side-effects of drugs and for evaluation of drug responsiveness]. Yakugaku Zasshi. 2004 Jun;124(6):293-9.</reference_text>
        <pubmed_id>15170064</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluvoxamine</name>
        <accession>HMDB14322</accession>
      </metabolite>
      <reference>
        <reference_text>McMahon LR, Cunningham KA: Role of 5-HT(2a) and 5-HT(2B/2C) receptors in the behavioral interactions between serotonin and catecholamine reuptake inhibitors. Neuropsychopharmacology. 2001 Mar;24(3):319-29.</reference_text>
        <pubmed_id>11166521</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluvoxamine</name>
        <accession>HMDB14322</accession>
      </metabolite>
      <reference>
        <reference_text>Millan MJ, Veiga S, Girardon S, Brocco M: Blockade of serotonin 5-HT1B and 5-HT2A receptors suppresses the induction of locomotor activity by 5-HT reuptake inhibitors, citalopram and fluvoxamine, in NMRI mice exposed to a novel environment: a comparison to other 5-HT receptor subtypes. Psychopharmacology (Berl). 2003 Aug;168(4):397-409. Epub 2003 Apr 30.</reference_text>
        <pubmed_id>12721776</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluvoxamine</name>
        <accession>HMDB14322</accession>
      </metabolite>
      <reference>
        <reference_text>Dell'Osso B, Allen A, Hollander E: Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder. Expert Opin Pharmacother. 2005 Dec;6(15):2727-40.</reference_text>
        <pubmed_id>16316311</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluvoxamine</name>
        <accession>HMDB14322</accession>
      </metabolite>
      <reference>
        <reference_text>Irons J: Fluvoxamine in the treatment of anxiety disorders.  Neuropsychiatr Dis Treat. 2005 Dec;1(4):289-99.</reference_text>
        <pubmed_id>18568110</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluvoxamine</name>
        <accession>HMDB14322</accession>
      </metabolite>
      <reference>
        <reference_text>Williams K, Wheeler DM, Silove N, Hazell P: Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2010 Aug 4;(8):CD004677.</reference_text>
        <pubmed_id>20687077</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phentermine</name>
        <accession>HMDB14337</accession>
      </metabolite>
      <reference>
        <reference_text>John CE, Jones SR: Voltammetric characterization of the effect of monoamine uptake inhibitors and releasers on dopamine and serotonin uptake in mouse caudate-putamen and substantia nigra slices. Neuropharmacology. 2007 Jun;52(8):1596-605. Epub 2007 Mar 16.</reference_text>
        <pubmed_id>17459426</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phentermine</name>
        <accession>HMDB14337</accession>
      </metabolite>
      <reference>
        <reference_text>Johnson GJ, Leis LA, Dunlop PC, Weir EK: The effect of the anorectic agent, d-fenfluramine, and its primary metabolite, d-norfenfluramine, on intact human platelet serotonin uptake and efflux. J Thromb Haemost. 2003 Dec;1(12):2663-8.</reference_text>
        <pubmed_id>14675103</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phentermine</name>
        <accession>HMDB14337</accession>
      </metabolite>
      <reference>
        <reference_text>Mekontso-Dessap A, Brouri F, Pascal O, Lechat P, Hanoun N, Lanfumey L, Seif I, Benhaiem-Sigaux N, Kirsch M, Hamon M, Adnot S, Eddahibi S: Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice. Circulation. 2006 Jan 3;113(1):81-9. Epub 2005 Dec 27.</reference_text>
        <pubmed_id>16380550</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phentermine</name>
        <accession>HMDB14337</accession>
      </metabolite>
      <reference>
        <reference_text>Rothman RB, Ayestas MA, Dersch CM, Baumann MH: Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension. Circulation. 1999 Aug 24;100(8):869-75.</reference_text>
        <pubmed_id>10458725</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phentermine</name>
        <accession>HMDB14337</accession>
      </metabolite>
      <reference>
        <reference_text>Zolkowska D, Rothman RB, Baumann MH: Amphetamine analogs increase plasma serotonin: implications for cardiac and pulmonary disease. J Pharmacol Exp Ther. 2006 Aug;318(2):604-10. Epub 2006 Apr 27.</reference_text>
        <pubmed_id>16644904</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tramadol</name>
        <accession>HMDB14339</accession>
      </metabolite>
      <reference>
        <reference_text>Barann M, Urban B, Stamer U, Dorner Z, Bonisch H, Bruss M: Effects of tramadol and O-demethyl-tramadol on human 5-HT reuptake carriers and human 5-HT3A receptors: a possible mechanism for tramadol-induced early emesis. Eur J Pharmacol. 2006 Feb 15;531(1-3):54-8. Epub 2006 Jan 19.</reference_text>
        <pubmed_id>16427041</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tramadol</name>
        <accession>HMDB14339</accession>
      </metabolite>
      <reference>
        <reference_text>Driessen B, Reimann W: Interaction of the central analgesic, tramadol, with the uptake and release of 5-hydroxytryptamine in the rat brain in vitro. Br J Pharmacol. 1992 Jan;105(1):147-51.</reference_text>
        <pubmed_id>1596676</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tramadol</name>
        <accession>HMDB14339</accession>
      </metabolite>
      <reference>
        <reference_text>Frink MC, Hennies HH, Englberger W, Haurand M, Wilffert B: Influence of tramadol on neurotransmitter systems of the rat brain.  Arzneimittelforschung. 1996 Nov;46(11):1029-36.</reference_text>
        <pubmed_id>8955860</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethylcitalopram</name>
        <accession>HMDB14021</accession>
      </metabolite>
      <reference>
        <reference_text>Eriksson E, Engberg G, Bing O, Nissbrandt H: Effects of mCPP on the extracellular concentrations of serotonin and dopamine in rat brain. Neuropsychopharmacology. 1999 Mar;20(3):287-96.</reference_text>
        <pubmed_id>10063489</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethylcitalopram</name>
        <accession>HMDB14021</accession>
      </metabolite>
      <reference>
        <reference_text>Maines LW, Keck BJ, Smith JE, Lakoski JM: Corticosterone regulation of serotonin transporter and 5-HT1A receptor expression in the aging brain. Synapse. 1999 Apr;32(1):58-66.</reference_text>
        <pubmed_id>10188639</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethylcitalopram</name>
        <accession>HMDB14021</accession>
      </metabolite>
      <reference>
        <reference_text>Vicentic A, Battaglia G, Carroll FI, Kuhar MJ: Serotonin transporter production and degradation rates: studies with RTI-76. Brain Res. 1999 Sep 11;841(1-2):1-10.</reference_text>
        <pubmed_id>10546982</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethylcitalopram</name>
        <accession>HMDB14021</accession>
      </metabolite>
      <reference>
        <reference_text>Dugar A, Keck BJ, Maines LW, Miller S, Njai R, Lakoski JM: Compensatory responses in the aging hippocampal serotonergic system following neurodegenerative injury with 5,7-dihydroxytryptamine. Synapse. 2001 Feb;39(2):109-21.</reference_text>
        <pubmed_id>11180498</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethylcitalopram</name>
        <accession>HMDB14021</accession>
      </metabolite>
      <reference>
        <reference_text>Dutta AK, Fei XS, Beardsley PM, Newman JL, Reith ME: Structure-activity relationship studies of 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives and their N-analogues: evaluation of O-and N-analogues and their binding to monoamine transporters. J Med Chem. 2001 Mar 15;44(6):937-48.</reference_text>
        <pubmed_id>11300876</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethylcitalopram</name>
        <accession>HMDB14021</accession>
      </metabolite>
      <reference>
        <reference_text>Plenge P, Wiborg O: High- and low-affinity binding of S-citalopram to the human serotonin transporter mutated at 20 putatively important amino acid positions. Neurosci Lett. 2005 Aug 5;383(3):203-8. Epub 2005 Apr 25.</reference_text>
        <pubmed_id>15955412</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethylcitalopram</name>
        <accession>HMDB14021</accession>
      </metabolite>
      <reference>
        <reference_text>Schloss P, Betz H: Heterogeneity of antidepressant binding sites on the recombinant rat serotonin transporter SERT1. Biochemistry. 1995 Oct 3;34(39):12590-5.</reference_text>
        <pubmed_id>7548008</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethylcitalopram</name>
        <accession>HMDB14021</accession>
      </metabolite>
      <reference>
        <reference_text>Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.</reference_text>
        <pubmed_id>9537821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethylcitalopram</name>
        <accession>HMDB14021</accession>
      </metabolite>
      <reference>
        <reference_text>Zhong H, Hansen KB, Boyle NJ, Han K, Muske G, Huang X, Egebjerg J, Sanchez C: An allosteric binding site at the human serotonin transporter mediates the inhibition of escitalopram by R-citalopram: kinetic binding studies with the ALI/VFL-SI/TT mutant. Neurosci Lett. 2009 Oct 25;462(3):207-12. Epub 2009 Jul 16.</reference_text>
        <pubmed_id>19616061</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethylcitalopram</name>
        <accession>HMDB14021</accession>
      </metabolite>
      <reference>
        <reference_text>Rasmussen TN, Plenge P, Bay T, Egebjerg J, Gether U: A single nucleotide polymorphism in the human serotonin transporter introduces a new site for N-linked glycosylation. Neuropharmacology. 2009 Sep;57(3):287-94. Epub 2009 Jun 3.</reference_text>
        <pubmed_id>19500602</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Atomoxetine</name>
        <accession>HMDB14434</accession>
      </metabolite>
      <reference>
        <reference_text>Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.</reference_text>
        <pubmed_id>9537821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Protriptyline</name>
        <accession>HMDB14488</accession>
      </metabolite>
      <reference>
        <reference_text>McDougle CJ, Epperson CN, Price LH, Gelernter J: Evidence for linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and obsessive compulsive disorder. Mol Psychiatry. 1998 May;3(3):270-3.</reference_text>
        <pubmed_id>9672904</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Protriptyline</name>
        <accession>HMDB14488</accession>
      </metabolite>
      <reference>
        <reference_text>Rouillon F, Blachier C, Dreyfus JP, Bouhassira M, Allicar MP: [Pharmaco-epidemiologic study of the use of antidepressant drugs in the general population]. Encephale. 1996 May;22 Spec No 1:39-48.</reference_text>
        <pubmed_id>8767026</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Protriptyline</name>
        <accession>HMDB14488</accession>
      </metabolite>
      <reference>
        <reference_text>Frazer A, Daws LC: Serotonin transporter function in vivo: assessment by chronoamperometry.  Ann N Y Acad Sci. 1998 Dec 15;861:217-29.</reference_text>
        <pubmed_id>9928259</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Protriptyline</name>
        <accession>HMDB14488</accession>
      </metabolite>
      <reference>
        <reference_text>Daws LC, Toney GM, Gerhardt GA, Frazer A: In vivo chronoamperometric measures of extracellular serotonin clearance in rat dorsal hippocampus: contribution of serotonin and norepinephrine transporters. J Pharmacol Exp Ther. 1998 Aug;286(2):967-76.</reference_text>
        <pubmed_id>9694957</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Protriptyline</name>
        <accession>HMDB14488</accession>
      </metabolite>
      <reference>
        <reference_text>Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.</reference_text>
        <pubmed_id>9537821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Protriptyline</name>
        <accession>HMDB14488</accession>
      </metabolite>
      <reference>
        <reference_text>Kovachich GB, Aronson CE, Brunswick DJ: Effect of repeated administration of antidepressants on serotonin uptake sites in limbic and neocortical structures of rat brain determined by quantitative autoradiography. Neuropsychopharmacology. 1992 Dec;7(4):317-24.</reference_text>
        <pubmed_id>1476595</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methylphenidate</name>
        <accession>HMDB14566</accession>
      </metabolite>
      <reference>
        <reference_text>Dresel SH, Kung MP, Huang X, Plossl K, Hou C, Shiue CY, Karp J, Kung HF: In vivo imaging of serotonin transporters with [99mTc]TRODAT-1 in nonhuman primates. Eur J Nucl Med. 1999 Apr;26(4):342-7.</reference_text>
        <pubmed_id>10199939</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methylphenidate</name>
        <accession>HMDB14566</accession>
      </metabolite>
      <reference>
        <reference_text>Izenwasser S, Coy AE, Ladenheim B, Loeloff RJ, Cadet JL, French D: Chronic methylphenidate alters locomotor activity and dopamine transporters differently from cocaine. Eur J Pharmacol. 1999 Jun 4;373(2-3):187-93.</reference_text>
        <pubmed_id>10414438</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methylphenidate</name>
        <accession>HMDB14566</accession>
      </metabolite>
      <reference>
        <reference_text>Stehouwer JS, Jarkas N, Zeng F, Voll RJ, Williams L, Owens MJ, Votaw JR, Goodman MM: Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. J Med Chem. 2006 Nov 16;49(23):6760-7.</reference_text>
        <pubmed_id>17154506</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Duloxetine</name>
        <accession>HMDB14619</accession>
      </metabolite>
      <reference>
        <reference_text>Chen F, Larsen MB, Sanchez C, Wiborg O: The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol. 2005 Mar;15(2):193-8.</reference_text>
        <pubmed_id>15695064</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Duloxetine</name>
        <accession>HMDB14619</accession>
      </metabolite>
      <reference>
        <reference_text>Troelsen KB, Nielsen EO, Mirza NR: Chronic treatment with duloxetine is necessary for an anxiolytic-like response in the mouse zero maze: the role of the serotonin transporter. Psychopharmacology (Berl). 2005 Oct;181(4):741-50. Epub 2005 Sep 29.</reference_text>
        <pubmed_id>16032412</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Duloxetine</name>
        <accession>HMDB14619</accession>
      </metabolite>
      <reference>
        <reference_text>Gould GG, Javors MA, Frazer A: Effect of Chronic Administration of Duloxetine on Serotonin and Norepinephrine Transporter Binding Sites in Rat Brain. Biol Psychiatry. 2006 Apr 29;.</reference_text>
        <pubmed_id>16650830</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Duloxetine</name>
        <accession>HMDB14619</accession>
      </metabolite>
      <reference>
        <reference_text>Mirza NR, Nielsen EO, Troelsen KB: Serotonin transporter density and anxiolytic-like effects of antidepressants in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2007 May 9;31(4):858-66. Epub 2007 Jan       30.</reference_text>
        <pubmed_id>17335951</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Duloxetine</name>
        <accession>HMDB14619</accession>
      </metabolite>
      <reference>
        <reference_text>Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ: Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry. 2004 Feb 1;55(3):320-2.</reference_text>
        <pubmed_id>14744476</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Duloxetine</name>
        <accession>HMDB14619</accession>
      </metabolite>
      <reference>
        <reference_text>Beique JC, Lavoie N, de Montigny C, Debonnel G: Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. Eur J Pharmacol. 1998 May 15;349(1):129-32.</reference_text>
        <pubmed_id>9669506</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Duloxetine</name>
        <accession>HMDB14619</accession>
      </metabolite>
      <reference>
        <reference_text>Karpa KD, Cavanaugh JE, Lakoski JM: Duloxetine pharmacology: profile of a dual monoamine modulator.  CNS Drug Rev. 2002 Winter;8(4):361-76.</reference_text>
        <pubmed_id>12481192</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Duloxetine</name>
        <accession>HMDB14619</accession>
      </metabolite>
      <reference>
        <reference_text>van Groeningen CJ, Peters GJ, Pinedo HM: Lack of effectiveness of combined 5-fluorouracil and leucovorin in patients with 5-fluorouracil-resistant advanced colorectal cancer. Eur J Cancer Clin Oncol. 1989 Jan;25(1):45-9.</reference_text>
        <pubmed_id>2784100</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Duloxetine</name>
        <accession>HMDB14619</accession>
      </metabolite>
      <reference>
        <reference_text>Jost W, Marsalek P: Duloxetine: mechanism of action at the lower urinary tract and Onuf's nucleus.  Clin Auton Res. 2004 Aug;14(4):220-7.</reference_text>
        <pubmed_id>15316838</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Duloxetine</name>
        <accession>HMDB14619</accession>
      </metabolite>
      <reference>
        <reference_text>Trivedi MH, Desaiah D, Ossanna MJ, Pritchett YL, Brannan SK, Detke MJ: Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine. Int Clin Psychopharmacol. 2008 May;23(3):161-9.</reference_text>
        <pubmed_id>18408530</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Duloxetine</name>
        <accession>HMDB14619</accession>
      </metabolite>
      <reference>
        <reference_text>Bymaster FP, Lee TC, Knadler MP, Detke MJ, Iyengar S: The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr Pharm Des. 2005;11(12):1475-93.</reference_text>
        <pubmed_id>15892657</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Duloxetine</name>
        <accession>HMDB14619</accession>
      </metabolite>
      <reference>
        <reference_text>Khullar V, Cardozo L, Dmochowski R: Mixed incontinence: current evidence and future perspectives.  Neurourol Urodyn. 2010 Apr;29(4):618-22.</reference_text>
        <pubmed_id>20432324</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Duloxetine</name>
        <accession>HMDB14619</accession>
      </metabolite>
      <reference>
        <reference_text>Carter NJ, McCormack PL: Duloxetine: a review of its use in the treatment of generalized anxiety disorder.  CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006.</reference_text>
        <pubmed_id>19480470</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Duloxetine</name>
        <accession>HMDB14619</accession>
      </metabolite>
      <reference>
        <reference_text>Hunziker ME, Suehs BT, Bettinger TL, Crismon ML: Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. Clin Ther. 2005 Aug;27(8):1126-43.</reference_text>
        <pubmed_id>16199241</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nortriptyline</name>
        <accession>HMDB14680</accession>
      </metabolite>
      <reference>
        <reference_text>Joyce PR, Mulder RT, Luty SE, McKenzie JM, Miller AL, Rogers GR, Kennedy MA: Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. Int J Neuropsychopharmacol. 2003 Dec;6(4):339-46.</reference_text>
        <pubmed_id>14604448</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nortriptyline</name>
        <accession>HMDB14680</accession>
      </metabolite>
      <reference>
        <reference_text>Wisner KL, Hanusa BH, Perel JM, Peindl KS, Piontek CM, Sit DK, Findling RL, Moses-Kolko EL: Postpartum depression: a randomized trial of sertraline versus nortriptyline.  J Clin Psychopharmacol. 2006 Aug;26(4):353-60.</reference_text>
        <pubmed_id>16855451</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nortriptyline</name>
        <accession>HMDB14680</accession>
      </metabolite>
      <reference>
        <reference_text>Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, Davis S, Kirshner MA, Houck PR, Stack JA, Reynolds CF, Kupfer DJ: Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology. 2000 Nov;23(5):587-90.</reference_text>
        <pubmed_id>11027924</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nortriptyline</name>
        <accession>HMDB14680</accession>
      </metabolite>
      <reference>
        <reference_text>Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ: Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry. 2004 Feb 1;55(3):320-2.</reference_text>
        <pubmed_id>14744476</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nortriptyline</name>
        <accession>HMDB14680</accession>
      </metabolite>
      <reference>
        <reference_text>Rausch JL, Moeller FG, Johnson ME: Initial platelet serotonin (5-HT) transport kinetics predict nortriptyline treatment outcome. J Clin Psychopharmacol. 2003 Apr;23(2):138-44.</reference_text>
        <pubmed_id>12640215</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nortriptyline</name>
        <accession>HMDB14680</accession>
      </metabolite>
      <reference>
        <reference_text>Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.</reference_text>
        <pubmed_id>9537821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Amoxapine</name>
        <accession>HMDB14683</accession>
      </metabolite>
      <reference>
        <reference_text>Spurlock G, Buckland P, O'Donovan M, McGuffin P: Lack of effect of antidepressant drugs on the levels of mRNAs encoding serotonergic receptors, synthetic enzymes and 5HT transporter. Neuropharmacology. 1994 Mar-Apr;33(3-4):433-40.</reference_text>
        <pubmed_id>7984281</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Amoxapine</name>
        <accession>HMDB14683</accession>
      </metabolite>
      <reference>
        <reference_text>Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.</reference_text>
        <pubmed_id>9537821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mazindol</name>
        <accession>HMDB14718</accession>
      </metabolite>
      <reference>
        <reference_text>Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.</reference_text>
        <pubmed_id>9537821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trazodone</name>
        <accession>HMDB14794</accession>
      </metabolite>
      <reference>
        <reference_text>Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.</reference_text>
        <pubmed_id>9537821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.</reference_text>
        <pubmed_id>9537821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Brown NL, Sirugue O, Worcel M: The effects of some slow channel blocking drugs on high affinity serotonin uptake by rat brain synaptosomes. Eur J Pharmacol. 1986 Apr 9;123(1):161-5.</reference_text>
        <pubmed_id>2940099</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paroxetine</name>
        <accession>HMDB14853</accession>
      </metabolite>
      <reference>
        <reference_text>Scholze P, Zwach J, Kattinger A, Pifl C, Singer EA, Sitte HH: Transporter-mediated release: a superfusion study on human embryonic kidney cells stably expressing the human serotonin transporter. J Pharmacol Exp Ther. 2000 Jun;293(3):870-8.</reference_text>
        <pubmed_id>10869387</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paroxetine</name>
        <accession>HMDB14853</accession>
      </metabolite>
      <reference>
        <reference_text>Preuss UW, Soyka M, Bahlmann M, Wenzel K, Behrens S, de Jonge S, Kruger M, Bondy B: Serotonin transporter gene regulatory region polymorphism (5-HTTLPR), [3H]paroxetine binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity. Psychiatry Res. 2000 Sep 25;96(1):51-61.</reference_text>
        <pubmed_id>10980326</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paroxetine</name>
        <accession>HMDB14853</accession>
      </metabolite>
      <reference>
        <reference_text>Haughey HM, Fleckenstein AE, Metzger RR, Hanson GR: The effects of methamphetamine on serotonin transporter activity: role of dopamine and hyperthermia. J Neurochem. 2000 Oct;75(4):1608-17.</reference_text>
        <pubmed_id>10987842</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paroxetine</name>
        <accession>HMDB14853</accession>
      </metabolite>
      <reference>
        <reference_text>Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, Davis S, Kirshner MA, Houck PR, Stack JA, Reynolds CF, Kupfer DJ: Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology. 2000 Nov;23(5):587-90.</reference_text>
        <pubmed_id>11027924</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paroxetine</name>
        <accession>HMDB14853</accession>
      </metabolite>
      <reference>
        <reference_text>Wihlback AC, Sundstrom-Poromaa I, Allard P, Mjorndal T, Spigset O, Backstrom T: Influence of postmenopausal hormone replacement therapy on platelet serotonin uptake site and serotonin 2A receptor binding. Obstet Gynecol. 2001 Sep;98(3):450-7.</reference_text>
        <pubmed_id>11530128</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paroxetine</name>
        <accession>HMDB14853</accession>
      </metabolite>
      <reference>
        <reference_text>Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.</reference_text>
        <pubmed_id>9537821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimipramine</name>
        <accession>HMDB14864</accession>
      </metabolite>
      <reference>
        <reference_text>Diamond M, Kelly JP, Connor TJ: Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90. Epub 2006 Jan 4.</reference_text>
        <pubmed_id>16388933</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimipramine</name>
        <accession>HMDB14864</accession>
      </metabolite>
      <reference>
        <reference_text>Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.</reference_text>
        <pubmed_id>9537821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Minaprine</name>
        <accession>HMDB14943</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Minaprine</name>
        <accession>HMDB14943</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cocaine</name>
        <accession>HMDB15043</accession>
      </metabolite>
      <reference>
        <reference_text>Patkar AA, Berrettini WH, Hoehe M, Thornton CC, Gottheil E, Hill K, Weinstein SP: Serotonin transporter polymorphisms and measures of impulsivity, aggression, and sensation seeking among African-American cocaine-dependent individuals. Psychiatry Res. 2002 Jun 1;110(2):103-15.</reference_text>
        <pubmed_id>12057823</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cocaine</name>
        <accession>HMDB15043</accession>
      </metabolite>
      <reference>
        <reference_text>Barker EL, Moore KR, Rakhshan F, Blakely RD: Transmembrane domain I contributes to the permeation pathway for serotonin and ions in the serotonin transporter. J Neurosci. 1999 Jun 15;19(12):4705-17.</reference_text>
        <pubmed_id>10366604</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cocaine</name>
        <accession>HMDB15043</accession>
      </metabolite>
      <reference>
        <reference_text>Corey JL, Quick MW, Davidson N, Lester HA, Guastella J: A cocaine-sensitive Drosophila serotonin transporter: cloning, expression, and electrophysiological characterization. Proc Natl Acad Sci U S A. 1994 Feb 1;91(3):1188-92.</reference_text>
        <pubmed_id>8302852</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cocaine</name>
        <accession>HMDB15043</accession>
      </metabolite>
      <reference>
        <reference_text>Carrera MR, Meijler MM, Janda KD: Cocaine pharmacology and current pharmacotherapies for its abuse.  Bioorg Med Chem. 2004 Oct 1;12(19):5019-30.</reference_text>
        <pubmed_id>15351386</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cocaine</name>
        <accession>HMDB15043</accession>
      </metabolite>
      <reference>
        <reference_text>Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.</reference_text>
        <pubmed_id>9537821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sibutramine</name>
        <accession>HMDB15237</accession>
      </metabolite>
      <reference>
        <reference_text>Vazquez Roque MI, Camilleri M, Clark MM, Tepoel DA, Jensen MD, Graszer KM, Kalsy SA, Burton DD, Baxter KL, Zinsmeister AR: Alteration of gastric functions and candidate genes associated with weight reduction in response to sibutramine. Clin Gastroenterol Hepatol. 2007 Jul;5(7):829-37. Epub 2007 Jun 4.</reference_text>
        <pubmed_id>17544870</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sibutramine</name>
        <accession>HMDB15237</accession>
      </metabolite>
      <reference>
        <reference_text>Heusser K, Engeli S, Tank J, Diedrich A, Wiesner S, Janke J, Luft FC, Jordan J: Sympathetic vasomotor tone determines blood pressure response to long-term sibutramine treatment. J Clin Endocrinol Metab. 2007 Apr;92(4):1560-3. Epub 2007 Feb 6.</reference_text>
        <pubmed_id>17284621</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sibutramine</name>
        <accession>HMDB15237</accession>
      </metabolite>
      <reference>
        <reference_text>Jordan J, Scholze J, Matiba B, Wirth A, Hauner H, Sharma AM: Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials. Int J Obes (Lond). 2005 May;29(5):509-16.</reference_text>
        <pubmed_id>15685250</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sibutramine</name>
        <accession>HMDB15237</accession>
      </metabolite>
      <reference>
        <reference_text>Heusser K, Tank J, Diedrich A, Engeli S, Klaua S, Kruger N, Strauss A, Stoffels G, Luft FC, Jordan J: Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects. Clin Pharmacol Ther. 2006 May;79(5):500-8.</reference_text>
        <pubmed_id>16678551</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sibutramine</name>
        <accession>HMDB15237</accession>
      </metabolite>
      <reference>
        <reference_text>Birkenfeld AL, Schroeder C, Boschmann M, Tank J, Franke G, Luft FC, Biaggioni I, Sharma AM, Jordan J: Paradoxical effect of sibutramine on autonomic cardiovascular regulation.  Circulation. 2002 Nov 5;106(19):2459-65.</reference_text>
        <pubmed_id>12417543</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sibutramine</name>
        <accession>HMDB15237</accession>
      </metabolite>
      <reference>
        <reference_text>Birkenfeld AL, Schroeder C, Pischon T, Tank J, Luft FC, Sharma AM, Jordan J: Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients--sibutramine and blood pressure. Clin Auton Res. 2005 Jun;15(3):200-6.</reference_text>
        <pubmed_id>15944869</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sibutramine</name>
        <accession>HMDB15237</accession>
      </metabolite>
      <reference>
        <reference_text>Tziomalos K, Krassas GE, Tzotzas T: The use of sibutramine in the management of obesity and related disorders: an update. Vasc Health Risk Manag. 2009;5(1):441-52.</reference_text>
        <pubmed_id>19475780</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sibutramine</name>
        <accession>HMDB15237</accession>
      </metabolite>
      <reference>
        <reference_text>Sharma B, Henderson DC: Sibutramine: current status as an anti-obesity drug and its future perspectives.  Expert Opin Pharmacother. 2008 Aug;9(12):2161-73.</reference_text>
        <pubmed_id>18671470</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sibutramine</name>
        <accession>HMDB15237</accession>
      </metabolite>
      <reference>
        <reference_text>Gomis Barbara R: [Pharmacological treatment of obesity].  Rev Med Univ Navarra. 2004 Apr-Jun;48(2):63-5.</reference_text>
        <pubmed_id>15382615</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sibutramine</name>
        <accession>HMDB15237</accession>
      </metabolite>
      <reference>
        <reference_text>Berke EM, Morden NE: Medical management of obesity.  Am Fam Physician. 2000 Jul 15;62(2):419-26.</reference_text>
        <pubmed_id>10929704</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sibutramine</name>
        <accession>HMDB15237</accession>
      </metabolite>
      <reference>
        <reference_text>Krahn LE, Moore WR, Altchuler SI: Narcolepsy and obesity: remission of severe cataplexy with sibutramine.  Sleep Med. 2001 Jan;2(1):63-65.</reference_text>
        <pubmed_id>11152984</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxepin</name>
        <accession>HMDB15273</accession>
      </metabolite>
      <reference>
        <reference_text>Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.</reference_text>
        <pubmed_id>9537821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxepin</name>
        <accession>HMDB15273</accession>
      </metabolite>
      <reference>
        <reference_text>Stahl SM: Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr. 2008 Dec;13(12):1027-38.</reference_text>
        <pubmed_id>19179941</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nefazodone</name>
        <accession>HMDB15280</accession>
      </metabolite>
      <reference>
        <reference_text>Owens MJ, Ieni JR, Knight DL, Winders K, Nemeroff CB: The serotonergic antidepressant nefazodone inhibits the serotonin transporter: in vivo and ex vivo studies. Life Sci. 1995;57(24):PL373-80.</reference_text>
        <pubmed_id>7475971</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nefazodone</name>
        <accession>HMDB15280</accession>
      </metabolite>
      <reference>
        <reference_text>Narayan M, Anderson G, Cellar J, Mallison RT, Price LH, Nelson JC: Serotonin transporter-blocking properties of nefazodone assessed by measurement of platelet serotonin. J Clin Psychopharmacol. 1998 Feb;18(1):67-71.</reference_text>
        <pubmed_id>9472845</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nefazodone</name>
        <accession>HMDB15280</accession>
      </metabolite>
      <reference>
        <reference_text>Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.</reference_text>
        <pubmed_id>9537821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nefazodone</name>
        <accession>HMDB15280</accession>
      </metabolite>
      <reference>
        <reference_text>Taylor DP, Carter RB, Eison AS, Mullins UL, Smith HL, Torrente JR, Wright RN, Yocca FD: Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug.  J Clin Psychiatry. 1995;56 Suppl 6:3-11.</reference_text>
        <pubmed_id>7649970</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nefazodone</name>
        <accession>HMDB15280</accession>
      </metabolite>
      <reference>
        <reference_text>Davis R, Whittington R, Bryson HM: Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs. 1997 Apr;53(4):608-36.</reference_text>
        <pubmed_id>9098663</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desipramine</name>
        <accession>HMDB15282</accession>
      </metabolite>
      <reference>
        <reference_text>Holmes A, Yang RJ, Murphy DL, Crawley JN: Evaluation of antidepressant-related behavioral responses in mice lacking the serotonin transporter. Neuropsychopharmacology. 2002 Dec;27(6):914-23.</reference_text>
        <pubmed_id>12464448</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desipramine</name>
        <accession>HMDB15282</accession>
      </metabolite>
      <reference>
        <reference_text>Gould GG, Altamirano AV, Javors MA, Frazer A: A comparison of the chronic treatment effects of venlafaxine and other antidepressants on serotonin and norepinephrine transporters. Biol Psychiatry. 2006 Mar 1;59(5):408-14. Epub 2005 Sep 2.</reference_text>
        <pubmed_id>16140280</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desipramine</name>
        <accession>HMDB15282</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou L, Huang KX, Kecojevic A, Welsh AM, Koliatsos VE: Evidence that serotonin reuptake modulators increase the density of serotonin innervation in the forebrain. J Neurochem. 2006 Jan;96(2):396-406. Epub 2005 Nov 21.</reference_text>
        <pubmed_id>16300628</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desipramine</name>
        <accession>HMDB15282</accession>
      </metabolite>
      <reference>
        <reference_text>Hoffman AF, Gerhardt GA: In vivo electrochemical studies of dopamine clearance in the rat substantia nigra: effects of locally applied uptake inhibitors and unilateral 6-hydroxydopamine lesions. J Neurochem. 1998 Jan;70(1):179-89.</reference_text>
        <pubmed_id>9422361</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desipramine</name>
        <accession>HMDB15282</accession>
      </metabolite>
      <reference>
        <reference_text>Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.</reference_text>
        <pubmed_id>9537821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexfenfluramine</name>
        <accession>HMDB15322</accession>
      </metabolite>
      <reference>
        <reference_text>Eddahibi S, Adnot S, Frisdal E, Levame M, Hamon M, Raffestin B: Dexfenfluramine-associated changes in 5-hydroxytryptamine transporter expression and development of hypoxic pulmonary hypertension in rats. J Pharmacol Exp Ther. 2001 Apr;297(1):148-54.</reference_text>
        <pubmed_id>11259539</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexfenfluramine</name>
        <accession>HMDB15322</accession>
      </metabolite>
      <reference>
        <reference_text>Russell BR, Laverty R: The effect of (R)-HA966 or ACEA 1021 on dexfenfluramine or (S)-MDMA-induced changes in temperature, activity, and neurotoxicity. Pharmacol Biochem Behav. 2001 Mar;68(3):565-74.</reference_text>
        <pubmed_id>11325413</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexfenfluramine</name>
        <accession>HMDB15322</accession>
      </metabolite>
      <reference>
        <reference_text>Rothman RB, Jayanthi S, Wang X, Dersch CM, Cadet JL, Prisinzano T, Rice KC, Baumann MH: High-dose fenfluramine administration decreases serotonin transporter binding, but not serotonin transporter protein levels, in rat forebrain. Synapse. 2003 Dec 1;50(3):233-9.</reference_text>
        <pubmed_id>14515341</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexfenfluramine</name>
        <accession>HMDB15322</accession>
      </metabolite>
      <reference>
        <reference_text>Johnson GJ, Leis LA, Dunlop PC, Weir EK: The effect of the anorectic agent, d-fenfluramine, and its primary metabolite, d-norfenfluramine, on intact human platelet serotonin uptake and efflux. J Thromb Haemost. 2003 Dec;1(12):2663-8.</reference_text>
        <pubmed_id>14675103</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexfenfluramine</name>
        <accession>HMDB15322</accession>
      </metabolite>
      <reference>
        <reference_text>Wang X, Baumann MH, Xu H, Rothman RB: 3,4-methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein. Synapse. 2004 Sep 15;53(4):240-8.</reference_text>
        <pubmed_id>15266556</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clomipramine</name>
        <accession>HMDB15372</accession>
      </metabolite>
      <reference>
        <reference_text>Alvarez JC, Gluck N, Arnulf I, Quintin P, Leboyer M, Pecquery R, Launay JM, Perez-Diaz F, Spreux-Varoquaux O: Decreased platelet serotonin transporter sites and increased platelet inositol triphosphate levels in patients with unipolar depression: effects of clomipramine and fluoxetine. Clin Pharmacol Ther. 1999 Dec;66(6):617-24.</reference_text>
        <pubmed_id>10613618</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clomipramine</name>
        <accession>HMDB15372</accession>
      </metabolite>
      <reference>
        <reference_text>Borkowska A, Pilaczynska E, Araszkiewicz A, Rybakowski J: [The effect of sertraline on cognitive functions in patients with obsessive-compulsive disorder]. Psychiatr Pol. 2002 Nov-Dec;36(6 Suppl):289-95.</reference_text>
        <pubmed_id>12647451</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clomipramine</name>
        <accession>HMDB15372</accession>
      </metabolite>
      <reference>
        <reference_text>Suhara T, Takano A, Sudo Y, Ichimiya T, Inoue M, Yasuno F, Ikoma Y, Okubo Y: High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch Gen Psychiatry. 2003 Apr;60(4):386-91.</reference_text>
        <pubmed_id>12695316</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clomipramine</name>
        <accession>HMDB15372</accession>
      </metabolite>
      <reference>
        <reference_text>Larsen AK, Brennum LT, Egebjerg J, Sanchez C, Halldin C, Andersen PH: Selectivity of (3)H-MADAM binding to 5-hydroxytryptamine transporters in vitro and in vivo in mice; correlation with behavioural effects. Br J Pharmacol. 2004 Mar;141(6):1015-23. Epub 2004 Mar 1.</reference_text>
        <pubmed_id>14993096</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clomipramine</name>
        <accession>HMDB15372</accession>
      </metabolite>
      <reference>
        <reference_text>Malizia AL, Melichar JM, Brown DJ, Gunn RN, Reynolds A, Jones T, Nutt DJ: Demonstration of clomipramine and venlafaxine occupation at serotonin reuptake sites in man in vivo. J Psychopharmacol. 1997;11(3):279-81.</reference_text>
        <pubmed_id>9305421</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clomipramine</name>
        <accession>HMDB15372</accession>
      </metabolite>
      <reference>
        <reference_text>Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.</reference_text>
        <pubmed_id>9537821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clomipramine</name>
        <accession>HMDB15372</accession>
      </metabolite>
      <reference>
        <reference_text>Gillman PK: Tricyclic antidepressant pharmacology and therapeutic drug interactions updated.  Br J Pharmacol. 2007 Jul;151(6):737-48. Epub 2007 Apr 30.</reference_text>
        <pubmed_id>17471183</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methamphetamine</name>
        <accession>HMDB15517</accession>
      </metabolite>
      <reference>
        <reference_text>Numachi Y, Ohara A, Yamashita M, Fukushima S, Kobayashi H, Hata H, Watanabe H, Hall FS, Lesch KP, Murphy DL, Uhl GR, Sora I: Methamphetamine-induced hyperthermia and lethal toxicity: role of the dopamine and serotonin transporters. Eur J Pharmacol. 2007 Oct 31;572(2-3):120-8. Epub 2007 Jun 27.</reference_text>
        <pubmed_id>17673199</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methamphetamine</name>
        <accession>HMDB15517</accession>
      </metabolite>
      <reference>
        <reference_text>Tellez R, Rocha L, Castillo C, Meneses A: Autoradiographic study of serotonin transporter during memory formation.  Behav Brain Res. 2010 Sep 1;212(1):12-26. Epub 2010 Mar 11.</reference_text>
        <pubmed_id>20226815</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methamphetamine</name>
        <accession>HMDB15517</accession>
      </metabolite>
      <reference>
        <reference_text>Sora I, Li B, Fumushima S, Fukui A, Arime Y, Kasahara Y, Tomita H, Ikeda K: Monoamine transporter as a target molecule for psychostimulants.  Int Rev Neurobiol. 2009;85:29-33.</reference_text>
        <pubmed_id>19607959</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Milnacipran</name>
        <accession>HMDB15602</accession>
      </metabolite>
      <reference>
        <reference_text>Leo RJ, Brooks VL: Clinical potential of milnacipran, a serotonin and norepinephrine reuptake inhibitor, in pain. Curr Opin Investig Drugs. 2006 Jul;7(7):637-42.</reference_text>
        <pubmed_id>16869117</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Milnacipran</name>
        <accession>HMDB15602</accession>
      </metabolite>
      <reference>
        <reference_text>Moret C, Charveron M, Finberg JP, Couzinier JP, Briley M: Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology. 1985 Dec;24(12):1211-9.</reference_text>
        <pubmed_id>3005901</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mianserin</name>
        <accession>HMDB15620</accession>
      </metabolite>
      <reference>
        <reference_text>Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.</reference_text>
        <pubmed_id>9537821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vilazodone</name>
        <accession>HMDB15637</accession>
      </metabolite>
      <reference>
        <reference_text>Page ME, Cryan JF, Sullivan A, Dalvi A, Saucy B, Manning DR, Lucki I: Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist. J Pharmacol Exp Ther. 2002 Sep;302(3):1220-7.</reference_text>
        <pubmed_id>12183683</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vilazodone</name>
        <accession>HMDB15637</accession>
      </metabolite>
      <reference>
        <reference_text>Adamec R, Bartoszyk GD, Burton P: Effects of systemic injections of vilazodone, a selective serotonin reuptake inhibitor and serotonin 1A receptor agonist, on anxiety induced by predator stress in rats. Eur J Pharmacol. 2004 Nov 3;504(1-2):65-77.</reference_text>
        <pubmed_id>15507223</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desvenlafaxine</name>
        <accession>HMDB15646</accession>
      </metabolite>
      <reference>
        <reference_text>Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, Abou-Gharbia M, Andree TH: Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor.  J Pharmacol Exp Ther. 2006 Aug;318(2):657-65. Epub 2006 May 4.</reference_text>
        <pubmed_id>16675639</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desvenlafaxine</name>
        <accession>HMDB15646</accession>
      </metabolite>
      <reference>
        <reference_text>Mason JN, Deecher DC, Richmond RL, Stack G, Mahaney PE, Trybulski E, Winneker RC, Blakely RD: Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter. J Pharmacol Exp Ther. 2007 Nov;323(2):720-9. Epub 2007 Aug 2.</reference_text>
        <pubmed_id>17673606</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desvenlafaxine</name>
        <accession>HMDB15646</accession>
      </metabolite>
      <reference>
        <reference_text>Perry R, Cassagnol M: Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder. Clin Ther. 2009 Jun;31 Pt 1:1374-404.</reference_text>
        <pubmed_id>19698900</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desvenlafaxine</name>
        <accession>HMDB15646</accession>
      </metabolite>
      <reference>
        <reference_text>Kamath J, Handratta V: Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence. Expert Rev Neurother. 2008 Dec;8(12):1787-97.</reference_text>
        <pubmed_id>19086875</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desvenlafaxine</name>
        <accession>HMDB15646</accession>
      </metabolite>
      <reference>
        <reference_text>Liebowitz MR, Tourian KA: Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials. Prim Care Companion J Clin Psychiatry. 2010;12(3). pii: PCC.09r00845.</reference_text>
        <pubmed_id>20944767</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desvenlafaxine</name>
        <accession>HMDB15646</accession>
      </metabolite>
      <reference>
        <reference_text>Reddy S, Kane C, Pitrosky B, Musgnung J, Ninan PT, Guico-Pabia CJ: Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician. Curr Med Res Opin. 2010 Jan;26(1):139-50.</reference_text>
        <pubmed_id>19919295</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexmethylphenidate</name>
        <accession>HMDB15647</accession>
      </metabolite>
      <reference>
        <reference_text>Dresel SH, Kung MP, Huang X, Plossl K, Hou C, Shiue CY, Karp J, Kung HF: In vivo imaging of serotonin transporters with [99mTc]TRODAT-1 in nonhuman primates. Eur J Nucl Med. 1999 Apr;26(4):342-7.</reference_text>
        <pubmed_id>10199939</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexmethylphenidate</name>
        <accession>HMDB15647</accession>
      </metabolite>
      <reference>
        <reference_text>Izenwasser S, Coy AE, Ladenheim B, Loeloff RJ, Cadet JL, French D: Chronic methylphenidate alters locomotor activity and dopamine transporters differently from cocaine. Eur J Pharmacol. 1999 Jun 4;373(2-3):187-93.</reference_text>
        <pubmed_id>10414438</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexmethylphenidate</name>
        <accession>HMDB15647</accession>
      </metabolite>
      <reference>
        <reference_text>Stehouwer JS, Jarkas N, Zeng F, Voll RJ, Williams L, Owens MJ, Votaw JR, Goodman MM: Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. J Med Chem. 2006 Nov 16;49(23):6760-7.</reference_text>
        <pubmed_id>17154506</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
